The global Primary Immunodeficiency Diseases Treatment market size is estimated at 9.8 billion USD with a CAGR of 6.7% during the forecasted period from 2021-2028.
The global Primary Immunodeficiency Diseases Treatment market size is estimated at 9.8 billion USD with a CAGR of 6.7% during the forecasted period from 2021-2028. A rare genetic disorder that damages the immune system is referred to Primary Immunodeficiency Diseases. In this condition, a person is prone to infection and other health issues. To overcome this medical condition there are different treatments available which boost the immune system. The key factor driving the growth of Primary Immunodeficiency Diseases Treatment market is attributed to increasing prevalence of diseases such as complement deficiencies, variable immune deficiency, Ataxia Telangiectasia, etc. In addition, increasing research & development activities along with rising therapeutic innovations is expected to boost the market size and demand for treatment. On the other hand, factors such as high cost of treatment is projected to limit the growth of Primary Immunodeficiency Diseases Treatment market. Also, risks associated with side effects of treatment such as allergies, renal failure, etc. may impede the growth of this market. Immunodeficiency disorders prevent a body from fighting infections and diseases. Immunodeficiency disorders are either congenital or acquired. Primary immune-deficiencies are disorders in which part of the body's immune system is missing or does not function normally, such that it is an inherited defect in the immune system that increases the susceptibility to infections. Fractionation separates the immunoglobulins and blood protein from plasma, which in turn, results in the development of immunoglobulins. Immunoglobulin therapy is useful in reducing the symptoms of autoimmune disease and a wide range of infections as they easily detect the microorganisms that are entering the body and assist the immune cells in neutralizing them. The primary immunodeficiency diseases market is driven by government approvals and support and increasing awareness regarding primary immunodeficiency diseases treatment. However, poor and critical reimbursement policies and the absence of adequate provision for diagnosis of primary immunodeficiency are hindering the market growth. Product enhancement and expansion are major strategies adopted by the key market players of primary immunodeficiency diseases treatment market.
Table of Content